In the top June M&A by deal value, MorphoSys AG entered into a definitive agreement to acquire public biopharma company Constellation Pharmaceuticals for $34.00 per share in cash (a 69% premium), representing a total equity value of $1.7bn. Through the acquisition, MorphoSys gets Constellation's two lead candidates pelabresib (Phase III BET inhibitor for myelofibrosis) and CPI-0209, an EZHR inhibitor in Phase II for solid and blood cancers. Financing reached $16.5bn in biopharma, $1.4bn in device, and $650m in diagnostics.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?